Money Control Place
  • Politics
  • Business
  • Stocks
  • Investing
  • Politics
  • Business
  • Stocks
  • Investing

Money Control Place

Business

CVS Health to no longer sell decongestants with phenylephrine

by October 22, 2023
October 22, 2023
CVS Health to no longer sell decongestants with phenylephrine

U.S. pharmacy chain CVS Health said on Thursday it is pulling some of the most common decongestants with phenylephrine as the only active ingredient from its shelves and will no longer sell them.

The move comes after a panel of advisers to U.S. health regulators raised doubts over the efficacy of the ingredient.

Last month, the panel refused to back the effectiveness of oral over-the-counter medicines made with phenylephrine, adding that no more trials were required to prove otherwise.

CVS said “other oral cough and cold products will continue to be offered to meet consumer needs.”

Phenylephrine was substituted for pseudoephedrine in many non-prescription cold and allergy medicines after the latter was restricted amid reports of abuse.

Phenylephrine is a major component used in some of popular products like Benadryl, Sudafed, GSK’s Advil and Kenvue’s Tylenol.

This post appeared first on NBC NEWS
0
FacebookTwitterGoogle +Pinterest
previous post
Abortion bans and anti-LGBTQ laws are complicating business travel
next post
China adopted ‘more dangerous’ tactics in 2022 as ‘only competitor’ to US, Pentagon warns in new report

Related Posts

EPA bans asbestos, a deadly carcinogen still in...

March 19, 2024

Walmart launches new grocery brand as it tries...

May 1, 2024

Popeyes is adding wings to its menu permanently

November 24, 2023

Law firm rescinds job offers to Harvard students...

October 18, 2023

Apple crushes Wall Street expectations as iPhone sales...

August 4, 2025

Sam Altman joins Microsoft to lead new AI...

November 20, 2023

State Department expands passport phone center hours, and...

July 18, 2023

Fitch downgrades U.S. credit rating from top score...

August 2, 2023

As Trump eyes more tariffs, South Korea remains...

February 15, 2025

Johnson & Johnson to pay $6.5 billion to...

May 3, 2024

    Get free access to all of the retirement secrets and income strategies from our experts! or Join The Exclusive Subscription Today And Get the Premium Articles Acess for Free


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Latest

    • S&P 500 Breaking Out Again: What This Means for Your Portfolio

    • CHARBONE presentera a la conference Hydrogen East et annonce le developpement d’un hub d’approvisionnement dans le marche de l’Atlantique via sa filiale

    • Tartisan Nickel Corp. Intersects 24.6 Metres of 0.71% Ni, 0.56% Cu Including 6.1 Metres of 1.17% Ni, 1.45% Cu at the Kenbridge Nickel-Copper-Cobalt Project, Northwestern Ontario

    • LaFleur Minerals Inc.Taking Key Steps to Advance Position in Prolific Gold Belt

    • NevGold Mobilizes Drill To Test Historical Leach Pads To Advance The Near-Term Antimony Production Scenario at Limo Butte

    • Cartier Cuts 7.1 g/t Au over 8.0 m at Portal ; New Shallow High-Grade Gold Zone Discovered

    Categories

    • Business (1,441)
    • Investing (3,613)
    • Politics (3,699)
    • Stocks (1,968)
    • Uncategorized (20)
    • About us
    • Contact us
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: MoneyControlPlace.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2026 moneycontrolplace.com | All Rights Reserved